Robert B Bazemore
CIK 1620152 · President & CEO · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$355.2K
Companies
7
Total Filings
46
Lifetime Open-Market Net
-$934.5K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARDX | Director | 68,006 | $5.08 | $345.8K | $0 | 11 | 2026-06-18 |
| NUVB | Director | — | $6.69 | — | $0 | 1 | 2026-05-26 |
| AKTX | Director | 1,116 | $8.43 | $9.4K | $0 | 4 | 2025-12-18 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 5,000 | $0.01 | $26 | $49.9K | 8 | 2025-05-23 |
| Epizyme, Inc. (EPZM) Delisted | President & CEO | 322,626 | $1.47 | $474.3K | -$984.4K | 16 | 2021-03-29 |
| Neon Therapeutics, Inc. (NTGN) Delisted | Director | — | — | — | $0 | 3 | 2020-05-06 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Chief Operating Officer | 0 | — | — | $0 | 3 | 2015-06-23 |
Recent Filings · Page 5 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-09-01 | Epizyme, Inc. (EPZM) Delisted | Grant (A) | +1,362 | $8.5K | EDGAR |
| 2016-06-06 | ARDX | Grant (A) | — | $0 | EDGAR |
| 2016-02-10 | Epizyme, Inc. (EPZM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-23 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Disp (D) | −35,000 | $0 | EDGAR |
| 2015-06-09 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2014-09-25 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Grant (A) | +30,000 | $0 | EDGAR |
Showing 41–46 of 46
Prev
Page 5 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.